Medical Management of HER2+ eBC

 

UCSF School of Medicine
P

ASCO 2021 Updates on Lisinopril or Carvedilol in Prevention of Trastuzumab-Induced Cardiotoxicity in HER2+ EBC: Longitudinal Changes of LVEF Below Normal Levels

By UCSF School of Medicine FEATURING Pamela Munster
By UCSF School of Medicine FEATURING Pamela Munster
569 views
July 6, 2021
0 Comments
Login to view comments. Click here to Login
Medical Management of HER2+ eBC
09:13
Ilana Schlam

Extended Adjuvant HER2-Targeted Therapy With Neratinib for HER2+ EBC…

10:20
Sarah Donahue

Effective Management and Prevention of Neratinib-Induced Diarrhea in…

19:18
Nisha Unni

CONTROL Trial Data on HER2+ EBC: Dosing and Improving Tolerability o…

08:47
Moffitt Cancer Center

Improved Tolerability of Neratinib in Patients With HER2+ EBC: The C…

Feat. H. Soliman
22:09
Yifan Tu

Bringing Diarrhea Under CONTROL: Adoption of Neratinib Dose Escalati…

30:01
Total Health

2021 Updates on Early Stage HER2+ Breast Cancer: Optimizing Adjuvant…

Feat. C. Vogel
06:57
Total Health

2021 ASCO Updates on HER2-Directed TKIs in the eBC Adjuvant Setting:…

Feat. J. Meisel, H. Soliman
12:44
Total Health

Adjuvant Therapy for HER2+ EBC: Surveying Clinical Data

Feat. J. Meisel, H. Soliman
26:06
Total Health

Advances in Management of Early HER2+ BC: What Data Do We Have?

Feat. T. Traina, L. Carey
15:52
Erika Hamilton

Managing AEs Associated With HER2-Targeted Therapy in EBC

13:13
UCSF School of Medicine

ASCO 2021 Updates on Lisinopril or Carvedilol in Prevention of Trast…

Feat. P. Munster
07:34
2021 Virtual Best of Breast

Postmenopausal Woman With Triple-Positive Breast Cancer: How to Appr…

Feat. J. Klemp, K. Mirabeau-Beale, K. Rojas, M. Lima
10:46
2021 Virtual Best of Breast

BC Side Effects & Survivorship: What Are the Most Common AI-Rela…

Feat. J. Klemp, K. Mirabeau-Beale, K. Rojas, M. Lima
07:26
Total Health

Expert Discussion on De-Escalation in Early Stage BC: Which Premenop…

Feat. H. Rugo, R. L. Mahtani
32:25
The Asian Oncology Society 1st Virtual International Conference

Residual Disease After Neoadjuvant Therapy - Updates on KATHERINE Tr…

Feat. E. Perez
08:23
Nadia Harbeck

ASCO 2021 Updates on De-escalated Neoadjuvant Pertuzumab+Trastuzumab…

17:59
Total Health

The Current State of HER2+ EBC Treatment: Overview of NeoSPHERE, TRY…

Feat. J. Meisel, H. Soliman
07:57
Laura Kennedy

ExteNET Final OS Data for HER2+ EBC: How Effective Is Neratinib?

06:58
2020 ASCO Virtual Direct™ Highlights

Early Stage HER2+ BC: How Effective Is Adjuvant Neratinib?

Feat. H. Rugo
07:43
Nancy Chan

Improved Tolerability of Neratinib in Patients With HER2+ EBC: The C…

36:13
Total Health

ESMO 2021 Updates on HER2+ EBC: Surveying the Recent Trials

Feat. L. Schwartzberg
17:55
Marija Balic

Association Between Treatment Duration and OS in Early-Stage HER2+ B…

05:44
SABCS 2021 Conference Coverage on VuMedi

SABCS 2021 on CNS Metastases as a Site of First Recurrence in Adjuva…

Feat. N. Lin